MedPath

Effect Of Pathyadi Kwatha In Dysfunctional Uterine Bleeding(Asrigdara)

Phase 3
Conditions
Health Condition 1: N939- Abnormal uterine and vaginal bleeding, unspecified
Registration Number
CTRI/2023/10/058721
Lead Sponsor
Dr Komal T Gayakwad
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Pratyatma lakshana of Asrigdara and DUB.

Asrigdara-Artava deergha kala Pravritti, Artava Ati Pravritti, Anruta kala Pravritti.

Exclusion Criteria

1.K/C/O – Diabetes mellitus, hypertension, tuberculosis.

2.Patient using intra uterine contraceptive device

3.K/C/O-Coagulation disorders

4.Patient with severe anemia HB% below 8 gms

5.K/C/O- Any pelvic pathology

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Effect of trial drug on improvement in the symptoms of Asrigdara(DUB).Timepoint: 4th day of menses, 10th day for three consecutive cycle
Secondary Outcome Measures
NameTimeMethod
Safety of the trial drug & Adverse Drug reaction & Aggravation in the symptoms of Asrigdara(DUB)Timepoint: 4th day of menses, 10th day for three consecutive cycle
© Copyright 2025. All Rights Reserved by MedPath